Patents by Inventor Viktor VINTONYAK

Viktor VINTONYAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230310373
    Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Application
    Filed: June 8, 2023
    Publication date: October 5, 2023
    Inventors: Ralf ANDERSKEWITZ, Florian BINDER, Matthias GRAUERT, Marc GRUNDL, Peter Wilhelm HAEBEL, Thorsten OOST, Alexander PAUTSCH, Stefan PETERS, Viktor VINTONYAK
  • Publication number: 20230131465
    Abstract: The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: September 9, 2022
    Publication date: April 27, 2023
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Daniela Gavina Berta, Marco Ferrara, Kirsten Gutsche, Ursula Mueller-Vieira, Scott Hobson, Frank Runge, Graeme Semple, Viktor Vintonyak, Yifeng Xiong
  • Patent number: 11583532
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • Patent number: 11319310
    Abstract: The present invention relates to compounds of general formula (I) wherein the variables X, R1, n, p and q are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 3, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Viktor Vintonyak
  • Patent number: 11254688
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: February 22, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
  • Patent number: 11136337
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: October 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Trieselmann, Cedrickx Godbout, Viktor Vintonyak
  • Publication number: 20210260027
    Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Application
    Filed: April 19, 2021
    Publication date: August 26, 2021
    Inventors: Ralf ANDERSKEWITZ, Florian BINDER, Matthias GRAUERT, Marc GRUNDL, Peter Wilhelm HAEBEL, Thorsten OOST, Alexander PAUTSCH, Stefan PETERS, Viktor VINTONYAK
  • Publication number: 20210053985
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 25, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Christoph HOENKE, Viktor VINTONYAK
  • Publication number: 20210038603
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 11, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Christoph HOENKE, Viktor VINTONYAK
  • Publication number: 20210040113
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 11, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Viktor VINTONYAK
  • Publication number: 20210040077
    Abstract: The present invention relates to compounds of general formula (I) wherein the variables X, R1, n, p and q are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 11, 2021
    Inventors: Thomas TRIESELMANN, Cedrickx GODBOUT, Viktor VINTONYAK
  • Publication number: 20200138780
    Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Inventors: Ralf ANDERSKEWITZ, Florian BINDER, Matthias GRAUERT, Marc GRUNDL, Peter Wilhelm HAEBEL, Thorsten OOST, Alexander PAUTSCH, Stefan PETERS, Viktor VINTONYAK
  • Publication number: 20190167636
    Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 6, 2019
    Inventors: Ralf ANDERSKEWITZ, Florian BINDER, Matthias GRAUERT, Marc GRUNDL, Peter Wilhelm HAEBEL, Thorsten OOST, Alexander PAUTSCH, Stefan PETERS, Viktor VINTONYAK
  • Patent number: 10308667
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak
  • Patent number: 10238633
    Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: March 26, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Florian Binder, Matthias Grauert, Marc Grundl, Peter Wilhelm Haebel, Thorsten Oost, Alexander Pautsch, Stefan Peters, Viktor Vintonyak
  • Publication number: 20180251476
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 6, 2018
    Inventors: Cédrickx GODBOUT, Thomas TRIESELMANN, Viktor VINTONYAK
  • Patent number: 9994591
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: June 12, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak
  • Publication number: 20180037594
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 8, 2018
    Inventors: Cédrickx GODBOUT, Thomas TRIESELMANN, Viktor VINTONYAK
  • Patent number: RE47636
    Abstract: This invention relates to a compound of formula I wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 8, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Viktor Vintonyak, Matthias Grauert, Marc Grundl, Alexander Pautsch
  • Patent number: RE49446
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 7, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak